Robert Dudley - Transcode Therapeutics CEO, CoFounder
| RNAZ Stock | USD 0.34 0.04 10.53% |
Insider
Robert Dudley is CEO, CoFounder of Transcode Therapeutics
| Age | 73 |
| Address | 6 Liberty Square, Boston, MA, United States, 02109 |
| Phone | 857 837 3099 |
| Web | https://www.transcodetherapeutics.com |
Robert Dudley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Dudley against Transcode Therapeutics stock is an integral part of due diligence when investing in Transcode Therapeutics. Robert Dudley insider activity provides valuable insight into whether Transcode Therapeutics is net buyers or sellers over its current business cycle. Note, Transcode Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Transcode Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Dudley over a month ago Acquisition by Robert Dudley of 6607 shares of Transcode Therapeutics at 2.5498 subject to Rule 16b-3 | ||
Robert Dudley over three months ago Acquisition by Robert Dudley of 135000 shares of Transcode Therapeutics at 2.45 subject to Rule 16b-3 | ||
Robert Dudley over a year ago Purchase by Robert Dudley of 98000 shares of Transcode Therapeutics | ||
Robert Dudley over a year ago Purchase by Robert Dudley of 6607 shares of Transcode Therapeutics |
Transcode Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.0795) % which means that it has lost $2.0795 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.487) %, meaning that it created substantial loss on money invested by shareholders. Transcode Therapeutics' management efficiency ratios could be used to measure how well Transcode Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.77 in 2024. Return On Capital Employed is likely to rise to -10.99 in 2024. At this time, Transcode Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 6.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 71.1 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gabriel BA | Immix Biopharma | 37 | |
| DSc MSE | Immix Biopharma | 75 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Andrew CPA | Cognition Therapeutics | 64 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| CPA MBA | Kodiak Sciences | 60 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Nandan BS | Immix Biopharma | 62 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| JD MBA | Immix Biopharma | N/A | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Chester III | Revelation Biosciences | 44 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| James Rolke | Revelation Biosciences | 55 | |
Management Performance
| Return On Equity | -10.49 | ||||
| Return On Asset | -2.08 |
Transcode Therapeutics Leadership Team
Elected by the shareholders, the Transcode Therapeutics' board of directors comprises two types of representatives: Transcode Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Transcode. The board's role is to monitor Transcode Therapeutics' management team and ensure that shareholders' interests are well served. Transcode Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Transcode Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| RN MBA, Senior Operations | ||
| Daniel MD, Chief Officer | ||
| Anna Moore, Scientific CoFounder | ||
| Zdravka Medarova, CoFounder Officer | ||
| Thomas MBA, CFO, CEO | ||
| Calais Pharm, Executive Board | ||
| Robert Dudley, CEO, CoFounder | ||
| Alan Freidman, Vice Relations | ||
| Qiyong Liu, VP Scientist |
Transcode Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Transcode Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.49 | ||||
| Return On Asset | -2.08 | ||||
| Current Valuation | 4.2 M | ||||
| Shares Outstanding | 17.27 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 1.99 % | ||||
| Number Of Shares Shorted | 215.52 K | ||||
| Price To Book | 3.59 X | ||||
| EBITDA | (17.97 M) | ||||
| Net Income | (18.55 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.